comparemela.com
Home
Live Updates
Off-Label Gabapentin Use Up Despite 'Dearth of Evidence' : c
Off-Label Gabapentin Use Up Despite 'Dearth of Evidence' : c
Off-Label Gabapentin Use Up Despite 'Dearth of Evidence'
The drug may be prescribed with sedating medications even after a 2019 warning from the FDA about such combinations.
Related Keywords
Michigan ,
United States ,
Ann Arbor ,
Michaele Johansen ,
Donovant Maust ,
,
Expenditure Panel ,
Drug Administration ,
Ann Arbor Va Center ,
National Institute On Drug Abuse ,
Clinical Management Research ,
University Of Michigan ,
Expenditure Panel Survey ,
Grant Family Medicine ,
Medical Expenditure Panel Survey ,
National Institute ,
Pain Management ,
Back Pain ,
Spain ,
Fibromyalgia ,
Chronic Pain ,
Neuropathic Pain ,
Central Nervous System ,
Ns ,
Addiction ,
Multiple Sclerosis Ms ,
S Multiple Sclerosis ,
Diabetic Peripheral Neuropathy ,
Opioids ,
Drug Abuse ,
Neuromuscular Blocking Drug ,
Muscle Relaxant ,
Neuromuscular Blocking Agent ,
Peripheral Neuropathy ,
Postherpetic Neuralgia ,
Diabetic Neuropathy ,
Diabetic Neuropathies ,